Patents by Inventor John Dixon Gray
John Dixon Gray has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10059774Abstract: There is disclosed compositions and methods relating to or derived from anti-CD38 antibodies. More specifically, there is disclosed fully human antibodies that bind CD38, CD38-antibody binding fragments and derivatives of such antibodies, and CD38-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.Type: GrantFiled: April 8, 2016Date of Patent: August 28, 2018Assignee: Sorrento Therapeutics, Inc.Inventors: Heyue Zhou, John Dixon Gray
-
Patent number: 10058609Abstract: There is disclosed compositions and methods relating to or derived from anti-PD-L1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-L1, PD-L1-binding fragments and derivatives of such antibodies, and PD-L1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-L1 related disorders or conditions, including various inflammatory disorders and various cancers.Type: GrantFiled: June 9, 2017Date of Patent: August 28, 2018Assignee: Sorrento Therapeutics, Inc.Inventors: Heyue Zhou, Randy Gastwirt, Barbara A. Swanson, John Dixon Gray, Gunnar F. Kaufmann
-
Patent number: 10035855Abstract: There is disclosed compositions and methods relating to or derived from anti-CD47 antibodies. More specifically, there is disclosed fully human antibodies that bind CD47, CD47-antibody binding fragments and derivatives of such antibodies, and CD47-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.Type: GrantFiled: March 4, 2016Date of Patent: July 31, 2018Assignee: SORRENTO THERAPEUTICS, INC.Inventors: Barbara A. Swanson, John Dixon Gray, Heyue Zhou
-
Patent number: 9969807Abstract: There is disclosed compositions and methods relating to or derived from anti-CD123 antibodies. More specifically, there is disclosed fully human antibodies that bind CD123, CD123-antibody binding fragments and derivatives of such antibodies, and CD123-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.Type: GrantFiled: April 8, 2016Date of Patent: May 15, 2018Assignee: Sorrento Therapeutics, Inc.Inventors: John Dixon Gray, Heyue Zhou
-
Patent number: 9951138Abstract: There is disclosed compositions and methods relating to or derived from anti-CCR2 antibodies. More specifically, there is disclosed fully human antibodies that bind CCR2, CCR2-binding fragments and derivatives of such antibodies, and CCR2-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having CCR2 related disorders or conditions.Type: GrantFiled: April 13, 2016Date of Patent: April 24, 2018Assignee: SORRENTO THERAPEUTICS, INC.Inventors: Dingqiu Huang, Barbara A. Swanson, John Dixon Gray, Heyue Zhou, Guodi Lu
-
Patent number: 9951144Abstract: There is disclosed compositions and methods relating to or derived from anti-CD38 antibodies. More specifically, there is disclosed fully human antibodies that bind CD38, CD38-antibody binding fragments and derivatives of such antibodies, and CD38-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.Type: GrantFiled: April 8, 2016Date of Patent: April 24, 2018Assignee: Sorrento Therapeutics, Inc.Inventors: John Dixon Gray, Heyue Zhou
-
Patent number: 9944707Abstract: There is disclosed compositions and methods relating to or derived from anti-EGFR antibodies. More specifically, there is disclosed fully human antibodies that bind EGFR, EGFR-binding fragments and derivatives of such antibodies, and EGFR-binding polypeptides comprising such fragments. Further still, there is disclosed antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having EGFR-related disorders or conditions.Type: GrantFiled: May 13, 2013Date of Patent: April 17, 2018Assignee: SORRENTO THERAPEUTICS, INC.Inventors: Heyue Zhou, Randy Gastwirt, Barbara A. Swanson, John Dixon Gray
-
Patent number: 9902772Abstract: There is disclosed compositions and methods relating to or derived from anti-LAG3 antibodies. More specifically, there is disclosed fully human antibodies that bind LAG3, LAG3-antibody binding fragments and derivatives of such antibodies, and LAG3-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.Type: GrantFiled: July 22, 2016Date of Patent: February 27, 2018Assignee: Sorrento Therapeutics, Inc.Inventors: Heyue Zhou, John Dixon Gray
-
Patent number: 9873741Abstract: There is disclosed compositions and methods relating to or derived from anti-TIM3 antibodies. More specifically, there is disclosed fully human antibodies that bind TIM3, TIM3-antibody binding fragments and derivatives of such antibodies, and TIM3-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.Type: GrantFiled: March 4, 2016Date of Patent: January 23, 2018Assignee: Sorrento Therapeutics, Inc.Inventors: John Dixon Gray, Heyue Zhou, Irina Krapf
-
Publication number: 20170313776Abstract: There is disclosed compositions and methods relating to or derived from anti-PD-1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-1, PD-1-binding fragments and derivatives of such antibodies, and PD-1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-1 related disorders or conditions, including various inflammatory disorders and various cancers.Type: ApplicationFiled: May 8, 2017Publication date: November 2, 2017Inventors: Heyue Zhou, Barbara A. Swanson, John Dixon Gray, Gunnar F. Kaufmann, Edwige Gros
-
Publication number: 20170291959Abstract: There is disclosed compositions and methods relating to or derived from anti-CD38 antibodies. More specifically, there is disclosed fully human antibodies that bind CD38, CD38-antibody binding fragments and derivatives of such antibodies, and CD38-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.Type: ApplicationFiled: April 8, 2016Publication date: October 12, 2017Applicant: Sorrento Therapeutics, Inc.Inventors: John Dixon Gray, Heyue Zhou
-
Publication number: 20170283501Abstract: There is disclosed compositions and methods relating to or derived from anti-c-Met antibodies. More specifically, there is disclosed fully human antibodies that bind c-Met, c-Met-binding fragments and derivatives of such antibodies, and c-Met-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having c-Met related disorders or conditions, including various inflammatory disorders and various cancers.Type: ApplicationFiled: June 21, 2013Publication date: October 5, 2017Inventors: Barbara A. Swanson, Heyue Zhou, Yan-Liang Zhang, Randy Gastwirt, John Dixon Gray
-
Publication number: 20170281765Abstract: There is disclosed compositions and methods relating to or derived from anti-PD-L1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-L1, PD-L1-binding fragments and derivatives of such antibodies, and PD-L1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-L1 related disorders or conditions, including various inflammatory disorders and various cancers.Type: ApplicationFiled: June 9, 2017Publication date: October 5, 2017Inventors: Heyue Zhou, Randy Gastwirt, Barbara A. Swanson, John Dixon Gray, Gunnar F. Kaufmann
-
Publication number: 20170233476Abstract: There is disclosed compositions and methods relating to or derived from anti-CTLA4 antibodies. More specifically, there is disclosed fully human antibodies that bind CTLA4, CTLA4-antibody binding fragments and derivatives of such antibodies, and CTLA4-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring either stimulation of immune responses or suppression.Type: ApplicationFiled: February 12, 2016Publication date: August 17, 2017Applicant: Sorrento Therapeutics, Inc.Inventors: Heyue Zhou, John Dixon Gray
-
Publication number: 20170226215Abstract: There is disclosed compositions and methods relating to or derived from anti-CD137 antibodies. More specifically, there is disclosed fully human antibodies that bind CD137, CD137-antibody binding fragments and derivatives of such antibodies, and CD137-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring either stimulation of immune responses or suppression. Diseases amenable to treatment is selected from the group consisting of cancers, autoimmune diseases and viral infections.Type: ApplicationFiled: February 22, 2016Publication date: August 10, 2017Applicant: Sorrento Therapeutics, Inc.Inventors: John Dixon Gray, Heyue Zhou
-
Publication number: 20170182161Abstract: There is disclosed compositions and methods relating to or derived from anti-PD-L1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-L1, PD-L1-binding fragments and derivatives of such antibodies, and PD-L1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-L1 related disorders or conditions, including various inflammatory disorders and various cancers.Type: ApplicationFiled: September 24, 2015Publication date: June 29, 2017Applicant: Sorrento Therapeutics, Inc.Inventors: Heyue Zhou, Randy Gastwirt, Barbara A. Swanson, John Dixon Gray, Gunnar F. Kaufmann
-
Publication number: 20170166644Abstract: There is disclosed compositions and methods relating to anti-VEGFR2 antibodies. More specifically, there is disclosed fully human antibodies that bind VEGFR2, VEGFR2-binding fragments and derivatives of such antibodies, and VEGFR2-binding polypeptides comprising such fragments. Further still, there is disclosed antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having various cancers.Type: ApplicationFiled: April 7, 2015Publication date: June 15, 2017Applicant: Sorrento Therapeutics, Inc.Inventors: Randy Gastwirt, Heyue Zhou, John Dixon Gray, Guodi Lu
-
Patent number: 9676853Abstract: There is disclosed compositions and methods relating to or derived from anti-PD-1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-1, PD-1-binding fragments and derivatives of such antibodies, and PD-1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-1 related disorders or conditions, including various inflammatory disorders and various cancers.Type: GrantFiled: May 31, 2014Date of Patent: June 13, 2017Assignee: Sorrento Therapeutics, Inc.Inventors: Heyue Zhou, Barbara A. Swanson, John Dixon Gray, Gunnar F. Kaufmann, Edwige Gros
-
Publication number: 20170022273Abstract: There is disclosed compositions and methods relating to or derived from anti-LAG3 antibodies. More specifically, there is disclosed fully human antibodies that bind LAG3, LAG3-antibody binding fragments and derivatives of such antibodies, and LAG3-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.Type: ApplicationFiled: July 22, 2016Publication date: January 26, 2017Inventors: Heyue Zhou, John Dixon Gray
-
Publication number: 20160297882Abstract: There is disclosed compositions and methods relating to or derived from anti-CD123 antibodies. More specifically, there is disclosed fully human antibodies that bind CD123, CD123-antibody binding fragments and derivatives of such antibodies, and CD123-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.Type: ApplicationFiled: April 8, 2016Publication date: October 13, 2016Applicant: Sorrento Therapeutics, Inc.Inventors: John Dixon Gray, Heyue Zhou